

PACIFIC EDGE COLLABORATES ON LAUNCH OF PATIENT COMMUNITY SITE

Bladdercancer.me patient community goes live for Bladder Cancer Awareness Month

Hershey, PA and Dunedin, NZ (9 May 2016): Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), is proud to announce the official launch of bladdercancer.me, an online bladder cancer patient community which provides support, tools and information for patients, their families and care-givers. The site's launch has been timed to coincide with Bladder Cancer Awareness Month in the United States of America.

Bladdercancer.me has been developed by digital health experts, Melon Health, in collaboration with a group of New Zealand and Australian companies, including Pacific Edge. It is unique in the way it helps patients self-manage their journey.

Pacific Edge is proud to be a major supporter of the site, which aims to “provide a place where patients, their families and care-givers can find emotional support, social connections, self-management tools and access to trustworthy resources and information.”

Bladder cancer, often referred to as the Cinderella of cancers, is the ninth most prevalent cancer globally and the fifth most common cancer among men. And it's on the rise, with over 600 people diagnosed in New Zealand every year and 75,000 new cases in the US annually.

Bladder cancer is treatable if it's detected early, but it has one of the highest recurrence rates of all cancers and requires regular monitoring.

Pacific Edge's Cxbladder diagnostic technology provides patients with an effective, non-invasive, urine based test that can be used to detect and monitor bladder cancer. With three tests in market and a fourth on the way, Cxbladder significantly outperforms the traditional cytology test and is a step change in how bladder cancer is detected and monitored.

New Look Pacific Edge Website Now Live

Pacific Edge is pleased to advise that its new look website www.pacifiedgedx.com is now live, designed to make it easy to find and view information of interest to investors and other interested parties.

ENDS

For more information, please contact:

David Darling, Chief Executive Officer, Pacific Edge Ltd P: +64 (3) 479 5800

OVERVIEW

www.pacifiedge.co.nz

www.pacifiedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies. Pacific Edge has three proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and better detection and management of urothelial cancer. Cxbladder Detect is available through the company's dedicated CLIA certified laboratories for customers in

New Zealand, Australia and the USA. Cxbladder Triage is available in New Zealand and Australia. Cxbladder Monitor launched in New Zealand in December 2015 and is anticipated being available in the US in 2016.

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with hematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the company's CLIA certified laboratories. Cxbladder Detect provides physicians and clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient's urine, with patient specific clinical factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

Refer to www.cxbladder.com for more information.